Worth reading
25Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateKey initiatives
01iPS drug discovery business
02Regenerative medicine business
03Consultations with PMDA are under way in preparation for conducting a Phase III trial in Japan
04Procedures are under way to apply for designation as an orphan drug
05Analysis of ropinirole's novel mechanism of action is under way
06Business development activities for overseas expansion are under way
Plan assumptionsThe market is expected to grow in an aging society
Non-financial targetsIndicator Start of a Phase III clinical trial in Japan / Target value Mid-2020s / Timing Targets, Indicator Completion of Phase III and submission of a new drug application / Target value Late 2020s / Timing Targets, Indicator Sales launch / Target value Late 2020s / Timing Targets
Size of the Target MarketMarket Market served by iPS drug discovery (global; psychiatric and neurological diseases) / Scale ¥6.1 trillion / Timing 2040 / Source Arthur D Little / FY2020 Survey on the Utilization of Disease-Specific iPS Cell Banks / Final Report (March 2021), Market Regenerative medicine market (global) / Scale ¥38.0 trillion / Timing 2050 / Source Ministry of Economy, Trade and Industry / Forecast of the Future Market Size of Regenerative Medicine (Japan; as of March 2020)
Risks identified by the company
There is no guarantee that the business will progress as assumed above, depending on the development status and clinical trial progress, among other factors
| Item | Details |
|---|---|
| Plan name | Materials on Business Plans and Growth Potential |
| Progress against the plan | Annual update |
| Non-financial targets | Indicator Start of a Phase III clinical trial in Japan / Target value Mid-2020s / Timing Targets, Indicator Completion of Phase III and submission of a new drug application / Target value Late 2020s / Timing Targets, Indicator Sales launch / Target value Late 2020s / Timing Targets |
| Plan assumptions | The market is expected to grow in an aging society |
| Key initiatives | iPS drug discovery business, Regenerative medicine business, Consultations with PMDA are under way in preparation for conducting a Phase III trial in Japan, Procedures are under way to apply for designation as an orphan drug, Analysis of ropinirole's novel mechanism of action is under way, Business development activities for overseas expansion are under way |
| Size of the Target Market | Market Market served by iPS drug discovery (global; psychiatric and neurological diseases) / Scale ¥6.1 trillion / Timing 2040 / Source Arthur D Little / FY2020 Survey on the Utilization of Disease-Specific iPS Cell Banks / Final Report (March 2021), Market Regenerative medicine market (global) / Scale ¥38.0 trillion / Timing 2050 / Source Ministry of Economy, Trade and Industry / Forecast of the Future Market Size of Regenerative Medicine (Japan; as of March 2020) |
| Risks identified | There is no guarantee that the business will progress as assumed above, depending on the development status and clinical trial progress, among other factors |
| Publication date | 27 March 2026 |
Items this document does not state (17)
Plan periodSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company did not specify the reason for updating and disclosing these materials.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.